FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

	OMB APPROVAL								
	OMB Number: 3235-0287								
l	Estimated average burden								
ı	hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HO WILLIAM					2. Issuer Name <b>and</b> Ticker or Trading Symbol RAPT Therapeutics, Inc. [ RAPT ]							ck all app Direc Office	licable) tor er (give title	ing Person(s) to I  10% C					
(Last) (First) (Middle) C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 12/15/2020								below	v) Chief Med	lical O	below) fficer			
(Street) SOUTH FRANCI	SCO CA		4080 Zip)		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Ind Line)							
(- 9)	(City) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)				tion 2A. Deemed Execution Date,		3. 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			A) or	5. Amo Securit Benefic Owned	unt of ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)					
									Code	v	Amount (A) or (D)		or P	rice	Reported Transaction(s) (Instr. 3 and 4)				(111501.4)
Common Stock 12/15				12/15/2	2020			S <sup>(1)</sup>		205	05 D \$		24.55	70,209		D			
Common	Stock			12/15/2	2020		S <sup>(1)</sup>		795	795 D \$		24.55	69,414		D				
		Tal								•	osed of, convertib			-	Owne	d			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Gecurity or Exercise (Month/Day/Year) if any				saction e (Instr. 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		De Se (In	s. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owr Fori Dire or Ir (I) (I	wnership	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A) (	(D)	Date Exercis	able	Expiration Date	Title	Amo or Num of Shar	ber					

## **Explanation of Responses:**

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

## Remarks:

/s/ Karen C. Lam, Attorney-in-12/1<u>5/2020</u> Fact for William Ho

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.